Zeltia Group
Calle Jose Abascal 2
Madrid
28003
Tel: 91-444-4500
Fax: 91-593-2954
Website: http://www.zeltia.com/
Email: zeltia@zeltia.com
27 articles about Zeltia Group
-
Johnson & Johnson Withdraws Cancer Drug Petition; Zeltia Group to Miss $10 Million Yondelis Payment After U.S. Setback
5/2/2011
-
Zeltia Group Fails to Win U.K. Backing for Ovarian Cancer Drug
3/11/2011
-
74 Percent EBITDA Improvement at Zeltia Group in 2010
2/25/2011
-
Australian Regulator Rejects Zeltia Group's Cancer Drug Yondelis
11/12/2010
-
Zeltia Group: Yondelis(R) Sales Expanded by 70 Percent
10/29/2010
-
Zeltia Group Reports Positive EBITDA in First Half of 2010
7/29/2010
-
Zeltia Group Achieves Consolidated EBITDA Break-Even in 1Q10
4/30/2010
-
Zeltia Group Achieves Consolidated EBITDA Break-Even in 1Q10
4/30/2010
-
Zeltia Group Revenues up 53.3%
2/26/2010
-
EU Agency Backs Zeltia Group Drug for Ovarian Cancer
9/25/2009
-
FDA Rejects Use Of Zeltia SA, Johnson & Johnson Drug Combo
9/14/2009
-
U.S. Panel Votes to Reject Johnson & Johnson, Zeltia Group Cancer Drug, Yondelis
7/17/2009
-
US FDA Staff Question Johnson & Johnson, Zeltia Group Cancer Drug Data
7/13/2009
-
Zeltia Group's Yondelis Gets First OK for Ovarian Cancer in the Philippines; U.S. FDA Panel to Review Drug July 15
7/10/2009
-
Zeltia Group's PharmaMar S.A. in Deal With US Medimetriks Pharmaceuticals, Inc.
6/10/2009
-
Zeltia Group Close to Deal with US Firm on Drug
6/4/2009
-
Zeltia Group's Yondelis to be Sold in Switzerland
2/6/2009
-
Zeltia Group's Yondelis Approved in Russia for Sarcoma
11/25/2008
-
Zeltia Group Says in Advanced Talks to License Aplidin
10/24/2008
-
Spain's Zeltia Group Presents Positive Zalypsis Data
10/23/2008